ArticleACS central science2023
Glow-in-the-Dark Infectious Disease Diagnostics Using CRISPR-Cas9-Based Split Luciferase Complementation.
Article in ACS central science, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed.
- Thermostable Bioluminescent Intercalating Dyes for Real-Time, Integrated Nucleic Acid Amplification and Detection.Angewandte Chemie (International ed. in English) · 2026Article
- Point of care antimicrobial susceptibility testing.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026Review
- Revolutionizing Healthcare With Paper-Based Nucleic Acid Testing.Exploration (Beijing, China) · 2026Review
- Spherical Nucleic Acid Stabilized Cage Type Three-Dimensional Electrochemiluminescence Probe for Sensitive and Amplification-Free Diagnosis of Infectious Diseases.Exploration (Beijing, China) · 2026Article
- Protein engineering: status report.Protein engineering, design & selection : PEDS · 2026Review
- Integrating CRISPR/Cas technology with clinical trials: Principles, progress and challenges.Asian journal of pharmaceutical sciences · 2025Review
- Ultrasensitive and long-lasting bioluminescence immunoassay for point-of-care viral antigen detection.Nature biomedical engineering · 2025Article
- Bioluminescent enzymatic biosensors: ways to manage their characteristics.Biophysical reviews · 2025Review
- DNA Origami-Based Luminescent Biosensors Enabling Smartphone Detection of Nucleic Acid Sequences.ACS omega · 2025Article
- Article
- Rapid and Wash-Free Anti-Drug Antibody Assay Enabled by a Complementary Nanoluciferase Biosensor.Analytical chemistry · 2025Article
- Bioluminescence in Clinical and Point-of-Care Testing.Biosensors · 2025Review
- Enzyme fragment complementation driven by nucleic acid hybridization sans self-labeling protein.Bioorganic chemistry · 2025Article
- Streamlined detection of Nipah virus antibodies using a split NanoLuc biosensor.Emerging microbes & infections · 2024Article
- Article
- CRISPR for companion diagnostics in low-resource settings.Lab on a chip · 2024Review
- Development of Luminescent Biosensors for Calprotectin.ACS chemical biology · 2024Article
- Bright Red Bioluminescence from Semisynthetic NanoLuc (sNLuc).ACS chemical biology · 2024Article
- Bioluminescent Intercalating Dyes for Ratiometric Nucleic Acid Detection.ACS chemical biology · 2024Article
- Bioluminescent detection of viral surface proteins using branched multivalent protein switches.RSC chemical biology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nucleic acid detection methods based on CRISPR and isothermal amplification techniques show great potential for point-of-care diagnostic applications. However, most current methods rely on fluorescent or lateral flow assay readout, requiring external excitation or postamplification reaction transfer. Here, we developed a bioluminescent nucleic acid sensor (LUNAS) platform in which target dsDNA is sequence-specifically detected by a pair of dCas9-based probes mediating split NanoLuc luciferase complementation. LUNAS is easily integrated with recombinase polymerase amplification (RPA), providing attomolar sensitivity in a rapid one-pot assay. A calibrator luciferase is included for a robust ratiometric readout, enabling real-time monitoring of the RPA reaction using a simple digital camera. We designed an RT-RPA-LUNAS assay that allows SARS-CoV-2 RNA detection without the need for cumbersome RNA isolation and demonstrated its diagnostic performance for COVID-19 patient nasopharyngeal swab samples. Detection of SARS-CoV-2 from samples with viral RNA loads of ∼200 cp/μL was achieved within ∼20 min, showing that RPA-LUNAS is attractive for point-of-care infectious disease testing.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.